January Therapeutics
Don Rindell has more than 30 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development, and device/technology strategy for several US and European pharmaceutical and medical device companies.
Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development. He recently managed the partnered pharmaco-diagnostic programs for Bristol Myers Squibb’s Translational Medicine initiatives for oncology and fibrosis. Previously he served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with companies including Shionogi Pharmaceuticals, Biocon, Takeda Pharmaceuticals and selected device delivery companies. He also provided management leadership to the Amylin Drug Delivery Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex.
Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.
This person is not in any teams
This person is not in any offices
January Therapeutics
January Therapeutics is developing next generation targeted anti-cancer therapies. Building upon the finding that protein-based nano-formulations have led to substantial improvements in the efficacy of known drugs, January is developing unique chemical matter to leverage well established anti-cancer mechanisms of action while adding new cancer targeting properties.